BSE: 0 | NSE: | Pharmaceuticals & Drugs |
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Recent Performance Summary not available for IPO
Recent Performance Summary not available for IPO
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | - | - |
| TTM Sales (₹ Cr.) | - | - |
| BVPS (₹.) ⓘ | - | - |
| Reserves (₹ Cr.) ⓘ | - | - |
| P/BV ⓘ | - | - |
| PE ⓘ | - | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | - / - |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | - |
| Equity (₹ Cr.) | - |
| Face Value (₹) | - |
| Industry PE ⓘ | - |
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|
| Sales | 2.05 | 14.43 | 21 |
| Operating Expenses ⓘ | 1.81 | 13.49 | 18.01 |
| Manufacturing Costs | 0.07 | 0.44 | 0.46 |
| Material Costs | 0.80 | 8.47 | 12.97 |
| Employee Cost | 0.52 | 2.78 | 2.60 |
| Other Costs ⓘ | 0.41 | 1.81 | 1.98 |
| Operating Profit ⓘ | 0.23 | 0.94 | 2.99 |
| Operating Profit Margin (%) | 11.4% | 6.5% | 14.2% |
| Other Income ⓘ | 0 | 0 | 0 |
| Interest ⓘ | 0.03 | 0.18 | 0.32 |
| Depreciation ⓘ | 0.06 | 0.16 | 0.42 |
| Exceptional Items ⓘ | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 0.15 | 0.59 | 2.25 |
| Tax ⓘ | 0.05 | 0.17 | 0.02 |
| Profit After Tax | 0.10 | 0.43 | 2.23 |
| PAT Margin (%) | 4.9% | 3.0% | 10.6% |
| Adjusted EPS (₹) | 0.8 | 3.4 | 3.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% |
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 0.93 | 1.36 | 6.76 | |||||||
| Share Capital ⓘ | 0.83 | 0.83 | 4 | |||||||
| Reserves ⓘ | 0.10 | 0.53 | 2.76 | |||||||
| Minority Interest | 0 | 0 | 0 | |||||||
| Debt | 1.32 | 3.16 | 1.68 | |||||||
| Long Term Debt | 0 | 0.62 | 0.54 | |||||||
| Short Term Debt | 1.32 | 2.53 | 1.14 | |||||||
| Trade Payables | 0.55 | 0.62 | 1.28 | |||||||
| Others Liabilities ⓘ | 0.43 | 0.96 | 1.10 | |||||||
| Total Liabilities ⓘ | 3.24 | 6.09 | 10.82 | |||||||
Fixed Assets | ||||||||||
| Gross Block | 0.64 | 1.72 | 1.93 | |||||||
| Accumulated Depreciation | 0.06 | 0.22 | 0.64 | |||||||
| Net Fixed Assets ⓘ | 0.58 | 1.50 | 1.29 | |||||||
| CWIP ⓘ | 0 | 0 | 0 | |||||||
| Investmentsⓘ | 0 | 0.02 | 0.03 | |||||||
| Inventories | 1.33 | 2.52 | 3.28 | |||||||
| Trade Receivables | 0.94 | 1.55 | 5.64 | |||||||
| Cash Equivalents | 0.05 | 0.25 | 0.07 | |||||||
| Others Assetsⓘ | 0.33 | 0.25 | 0.51 | |||||||
| Total Assets ⓘ | 3.24 | 6.09 | 10.82 | |||||||
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -1.18 | -0.55 | -1.39 |
| PBT ⓘ | 0.15 | 0.59 | 2.25 |
| Adjustment ⓘ | 0.09 | 0.34 | 0.74 |
| Changes in Working Capital ⓘ | -1.38 | -1.32 | -4.36 |
| Tax Paid ⓘ | -0.04 | -0.17 | -0.02 |
| Cash Flow From Investing Activity ⓘ | -0.64 | -1.10 | -0.23 |
| Capex | -0.64 | -1.08 | -0.21 |
| Net Investments | 0 | -0.02 | -0.02 |
| Others ⓘ | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | 1.87 | 1.84 | 1.44 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0.62 | -0.08 |
| Interest Paid ⓘ | -0.03 | -0.18 | -0.32 |
| Dividend Paid ⓘ | 0 | 0 | 0 |
| Others ⓘ | 1.90 | 1.40 | 1.84 |
| Net Cash Flow ⓘ | 0.05 | 0.19 | -0.18 |
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 10.7 | 37.29 | 55.02 | |||||||
| ROCE (%) | 7.93 | 22.76 | 39.18 | |||||||
| Asset Turnover Ratio | 0.63 | 3.09 | 2.54 | |||||||
| PAT to CFO Conversion(x) | -11.8 | -1.28 | -0.62 | Working Capital Days | ||||||
| Receivable Days | 168 | 32 | 61 | |||||||
| Inventory Days | 237 | 49 | 49 | |||||||
| Payable Days | 251 | 25 | 27 | |||||||